{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:54:32Z","timestamp":1787014472350,"version":"build-2736575974"},"reference-count":149,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T00:00:00Z","timestamp":1318032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Aurora kinases play an important role in the control of the cell cycle and have been implicated in tumourigenesis in a number of cancers. Among the haematological malignancies, overexpression of Aurora kinases has been reported in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia, multiple myeloma, aggressive non\u2010Hodgkin lymphoma and Hodgkin lymphoma. A large number of Aurora kinase inhibitors are currently in different stages of clinical development. In addition to varying in their selectivity for the different Aurora kinases, some also have activity directed at other cellular kinases involved in important molecular pathways in cancer cells. This review summarizes the biology of Aurora kinases and discusses why they may be good therapeutic targets in different haematological cancers. We describe preclinical data that has served as the rationale for investigating Aurora kinase inhibitors in different haematological malignancies, and summarize published results from early phase clinical trials. While the anti\u2010tumour effects of Aurora kinase inhibitors appear promising, we highlight important issues for future clinical research and suggest that the optimal use of these inhibitors is likely to be in combination with cytotoxic agents already in use for the treatment of various haematological cancers.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08898.x","type":"journal-article","created":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T02:25:17Z","timestamp":1318040717000},"page":"561-579","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["The potential role of Aurora kinase inhibitors in haematological malignancies"],"prefix":"10.1111","volume":"155","author":[{"given":"Sherif S.","family":"Farag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208752"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2003.10.013"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1534-5807(04)00025-5"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:NEON.0000021784.33421.05"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.013136"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.11.3052"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.06.003"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701140104"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000111"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21370"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1245"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00412-008-0165-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0797-260"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.729"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-097774"},{"key":"e_1_2_8_17_1","first-page":"3232","article-title":"Preliminary clinical activity in a phase I trial of the BCR\u2010ABL\/IGF\u20101R\/Aurora Kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation","volume":"112","author":"Cortes J.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_18_1","first-page":"2967","article-title":"A phase I dose escalation study of KW\u20102449, an oral multi\u2010kinase inhibitor against FLT3, Abl, FGFR1 and Aurora in patients with relapsed\/refractory AML, ALL and MDS or resistant\/intolerant CML","volume":"112","author":"Cortes J.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_19_1","first-page":"864","article-title":"Danusertib hydrochloride (PHA\u2010739358), a multi\u2010kinase Aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"114","author":"Cortes\u2010Franco J.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23371"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.434"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200208091"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.10.009"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.01108"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701824544"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06913.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(03)00166-0"},{"key":"e_1_2_8_28_1","first-page":"1957","article-title":"Clinical activity of a novel multiple tyrosine kinase and Aurora kinase inhibitor, ENMD\u20102076, against multiple myeloma: interim phase I trial results","volume":"116","author":"Farag S.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04219"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0574"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"e_1_2_8_32_1","first-page":"2518","article-title":"Phase I and pharmacodynamic trial of AT9283, an Aurora kinase inhibitor, in patients with refractory leukemia","volume":"26","author":"Foran J.M.","year":"2008","journal-title":"ASCO Meeting Abstracts"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209494"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200404001"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-2179"},{"issue":"21","key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1242\/jcs.112.21.3591","article-title":"Aurora\/Ipl1p\u2010related kinases, a new oncogenic family of mitotic serine\u2010threonine kinases","volume":"112","author":"Giet R.","year":"1999","journal-title":"Journal of Cell Science"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3353"},{"key":"e_1_2_8_38_1","first-page":"3273","article-title":"Phase 2 study of MLN8237, an investigational Aurora A kinase (AAK) inhibitor In patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS)","volume":"116","author":"Goldberg S.L.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113175"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-259523"},{"key":"e_1_2_8_41_1","first-page":"1420","article-title":"Activation and overexpression of centrosome kinase BTAK\/Aurora\u2010A in human ovarian cancer","volume":"9","author":"Gritsko T.M.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1144"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2005.03.041"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04311.x"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1003"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203650"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200208092"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1902"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00642-1"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04254"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251074"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203609"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-178350"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099325"},{"key":"e_1_2_8_55_1","article-title":"Anti\u2010tumor activity of the Aurora a inhibitor MLN8237 in diffuse large B\u2010cell lymphoma preclinical models","volume":"112","author":"Huck J.J.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0067"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2009.106"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1057-03"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.10.6621"},{"key":"e_1_2_8_61_1","first-page":"656","article-title":"Phase I study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside in patients with acute myeloid leukemia (AML)","volume":"116","author":"Kantarjian H.M.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023789416385"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1279"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-009-9184-9"},{"key":"e_1_2_8_65_1","article-title":"The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib","author":"Kelly K.R.","year":"2010","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"e_1_2_8_66_1","first-page":"1789","article-title":"Overexpression and amplification of STK15 in human gliomas","volume":"25","author":"Klein A.","year":"2004","journal-title":"International Journal of Oncology"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E05-12-1133"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2006.03.056"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1752"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2259"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200204155"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2005.09.014"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E05-08-0727"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2964"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0228"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200812045"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202606599"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1167000"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283350dd1"},{"key":"e_1_2_8_80_1","first-page":"2080","article-title":"Phase I\/II study to assess the safety and efficacy of the Aurora B kinase inhibitor, AZD1152, in patients with advanced acute myeloid leukemia","volume":"114","author":"Lowenberg B.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M805880200"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07185"},{"key":"e_1_2_8_83_1","article-title":"AT9283, a novel pan\u2010aurora\/JAK\u20102 kinase inhibitor suppresses tumor growth in aggressive B\u2010cell non\u2010hodgkin\u2019s lymphoma","volume":"116","author":"Mahadevan D.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608798104"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22430"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0641-1"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1200"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.03326"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.15"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404832"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.02.010"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.09.005"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(02)00848-5"},{"key":"e_1_2_8_94_1","article-title":"The Aurora kinase inhibitor MLN8237 has potent anticancer activity in CML and Ph+ ALL models and significantly increases the efficacy of nilotinib","volume":"112","author":"Nawrocki S.T.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07891.x"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.4.3817"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1095920"},{"key":"e_1_2_8_98_1","first-page":"1205","article-title":"Expression of fibroblast growth factor and FGF\u2010receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation","volume":"15","author":"Otsuki T.","year":"1999","journal-title":"International Journal of Oncology"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/603925"},{"key":"e_1_2_8_100_1","first-page":"2799","article-title":"Phase I study of an investigational Aurora A kinase inhibitor MLN8237 In patients with advanced hematologic malignancies","volume":"116","author":"Padmanabhan S.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04814.x"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.1.101"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2007.03.013"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.3.992.003k29_992_998"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8012129"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177030"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.01.017"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2324"},{"key":"e_1_2_8_109_1","first-page":"1275","article-title":"The putative serine\/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas","volume":"10","author":"Reichardt W.","year":"2003","journal-title":"Oncology Reports"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2257"},{"key":"e_1_2_8_111_1","first-page":"2994","article-title":"AT9283, a small molecule multi\u2010targeted kinase inhibitor with potent activity against Aurora kinase and STAT3 In combination with lenalidomide results in synergistic anti\u2010myeloma activity","volume":"116","author":"Santo L.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3012"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/cm.20039"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402966101"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2006.01.007"},{"key":"e_1_2_8_116_1","first-page":"3247","article-title":"Activity of Serono\u2010AS703569, a dual inhibitor of Bcr\u2010Abl and Aurora kinases in Bcr\u2010Abl transformed cells, is dependent on Aurora B inhibition, and is not affected by the presence of the highly imatinib resistant Bcr\u2010Abl mutation T315I","volume":"114","author":"Seitz A.K.","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201065"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.17.1320"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.03.031"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199307"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602779"},{"key":"e_1_2_8_122_1","first-page":"2963","article-title":"Phase I, dose\u2010escalation study of 2 dosing regimens of AS703569, an inhibitor of aurora and other kinases, administered orally in patients with advanced hematological malignancies","volume":"112","author":"Sonet A.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9405-7"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.11.004"},{"key":"e_1_2_8_126_1","first-page":"1104","article-title":"Activity of the multi\u2010targeted kinase inhibitor, AT9283 on imatinib\u2010resistant CML models","volume":"112","author":"Tanaka R.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208293"},{"key":"e_1_2_8_128_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.3.667"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25178"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200604032"},{"key":"e_1_2_8_131_1","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-3-10"},{"key":"e_1_2_8_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.07.015"},{"key":"e_1_2_8_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08248.x"},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307700101"},{"key":"e_1_2_8_135_1","volume-title":"The Biology of Cancer","author":"Weinberg R.A.","year":"2007"},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.02.034"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000110"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001683615"},{"key":"e_1_2_8_139_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.8.2434"},{"key":"e_1_2_8_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.12.168"},{"key":"e_1_2_8_141_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-2907"},{"key":"e_1_2_8_142_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22154"},{"key":"e_1_2_8_143_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073700"},{"key":"e_1_2_8_144_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1008366107"},{"key":"e_1_2_8_145_1","first-page":"3307","article-title":"A phase I study of ENMD\u20102076 in patients with relapsed or refractory leukemia","volume":"116","author":"Yee K.W.L.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_146_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2443.2005.00824.x"},{"key":"e_1_2_8_147_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2788"},{"key":"e_1_2_8_148_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.584869"},{"key":"e_1_2_8_149_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2559"},{"key":"e_1_2_8_150_1","doi-asserted-by":"publisher","DOI":"10.1038\/2496"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08898.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08898.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:30:56Z","timestamp":1697441456000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08898.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,8]]},"references-count":149,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08898.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08898.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,8]]},"assertion":[{"value":"2011-10-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}